Analysis of the United States Glaucoma Pharmaceuticals Market
NEW YORK, March 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Analysis of the United States Glaucoma Pharmaceuticals Market
http://www.reportlinker.com/p0770719/Analysis-of-the-United-States-Glaucoma-Pharmaceuticals-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This research service covers the United States glaucoma pharmaceuticals market from 2008 to 2016, with 2010 as the base year. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: prostaglandins, beta-blockers, alpha-adrenerigic agonists, carbonic anhydrase inhibitors, and fixed-dose combinations.
Table of Contents
Executive Summary 4
Market Overview 10
Total Glaucoma Pharmaceuticals Market -
•External Challenges: Drivers and Restraints 18
•Forecasts and Trends 26
•Demand Analysis 38
•Market Share and Competitive Analysis 40
Prostaglandin Segment Breakdown 56
Beta-Blocker Segment Breakdown 67
Alpha-Adrenergic Agonist Segment Breakdown 78
Carbonic Anhydrase Inhibitor Segment Breakdown 89
Fixed-Dose Combination Segment Breakdown 100
The Last Word (Conclusions and Implications) 111
Appendix 115
To order this report:
Drug and Medication Industry: Analysis of the United States Glaucoma Pharmaceuticals Market
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article